IPCA Laboratories share news and announcements
NSE: IPCALABBSE: 524494Pharmaceuticals & BiotechnologyMid Cap
Last close ₹1,953.30up ₹49.80 (2.62%)BSE ₹1,951.25
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,903.50.
52-week range of traded prices to 23 Oct 2026
₹1,251.60Low, 24 Oct 2025₹2,038.00High, 18 Sep 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹49,556 Cr229th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 13 Aug 2026
- 37.8
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 6.1
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.31%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 13 Aug 2026
- 17.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 13 Aug 2026
- 17.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.07
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 3,18,78151.9% delivered
IPCA Laboratories share news and announcements
771 announcements, routine notices left out, newest first. Page 10 of 16.
Oct 2015
Sep 2015
Jul 2015
31 Jul · Disclosure of Voting Pattern - Clause 35A
2 Jul · Dividend
Dividend of Re. 1 per share (50%) which if sanctioned will be paid on or before August 22, 2015.2 Jul · Meeting
Register of Members and Share Transfer Books of the Company shall remain closed from July 24, 2015 to July 30, 2015 for the purpose of Annual General Meeting scheduled to be held on July 30, 2015 and payment of final dividend.
May 2015
30 May · Dividend
Board of Directors of the Company at its meeting held on May 30, 2015 has recommended a dividend of Re. 1/- per share (50%) for the financial year ended March 31, 2015.
Apr 2015
Mar 2015
Feb 2015
Jan 2015
23 Jan · Legal
Exchange has sought clarification from IPCA Laboratories Limited with respect to recent news item captioned "IPCA Labs Gets US FDA Import Alert For Ratlam Plant". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Dec 2014
29 Dec · Legal
Exchange had sought clarification from IPCA Laboratories Limited with respect to a news item captioned "Indian pharma now under Canada lens". The Company has clarified that "Health Canada has requested the Company to voluntarily quarantine any drugs manufactured at the Company's Indore SEZ, Pithampur formulations manufacturing unit intended for Canadian market as an interim measure and precautionary step in view of the US-FDA audit observations made regarding GMP deficiencies at the said manufacturing unit. The Company does not generate any material business out of the said manufacturing unit from the Canandian market. The Company is fully committed in resolving this issue at the earliest. The Company is also committed to its philosophy of highest quality in manufacturing, operations, systems, intergrity and cGMP culture".26 Dec · Legal
Exchange has sought clarification from IPCA Laboratories Limited with respect to news item captioned "Indian pharma now under Canada lens". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Nov 2014
Oct 2014
29 Oct · Board meeting
Inter-alia, to take on record the Unaudited Financial Results for the quarter and half year ended September 30, 2014.
Sep 2014
Aug 2014
21 Aug · Disclosure of Voting Pattern - Clause 35A
4 Aug · Disclosure of Voting Pattern - Clause 35A
Jul 2014
2 Jul · Meeting
Register of Members and Share Transfer Books of the Company will remain closed from July 22, 2014 to July 31, 2014 (both days inclusive) for the purpose of Annual General Meeting scheduled to be held on July 31, 2014 and payment of final dividend.2 Jul · Dividend
Final dividend of Rs. 2.50 (125%) if sanctioned will be paid on or before August 22, 2014.
Jun 2014
May 2014
29 May · Dividend
Board of Directors of the Company at its meeting held on May 29, 2014 has recommended a final dividend of Rs.2.50 per share (125%) for the financial year ended March 31, 2014.
Apr 2014